Core sedating antihistamine product information

Rated 3.89/5 based on 877 customer reviews

Safety and efficacy of loratadine (Sch- 29851): a new non-sedating antihistamine in seasonal allergic rhinitis.

Pharmacokinetic-pharmacodynamic relationships of H- antihistamines.

American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. Claritin tablets, syrup and rapidly disintegrating tablets prescribing information.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

Focus on loratadine: a new second-generation nonsedating H1-receptor antagonist.

Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis.

core sedating antihistamine product information-77

core sedating antihistamine product information-85

core sedating antihistamine product information-71

Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine. Claritin-D 24 Hour (loratadine and pseudoephedrine sulfate) extended-release tablets prescribing information. Schering Corp, Kenilworth, NJ: Personal communication. Loratadine: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Over-the-counter drugs: establishment of a monograph for OTC cold, cough, allergy, bronchodilator and antiasthmatic products.

Leave a Reply